Skip to main content
Fig. 9 | The Journal of Headache and Pain

Fig. 9

From: Therapeutic novelties in migraine: new drugs, new hope?

Fig. 9

Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with fremanezumab. A darker bar indicates a higher dose. *NCT02629861 (left); 225 mg vs. placebo, p < 0.001; 675 mg vs. placebo, p < 0.001. NCT02629861 (right); 225 mg vs. placebo, p < 0.001; 675 mg vs. placebo, p < 0.001

Back to article page
\